Patents by Inventor Etienne Huvelle

Etienne Huvelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8562532
    Abstract: A phase analysis technique provides for quantification of regional wall motion asynchrony from endocardial border contours generated from two-dimensional echocardiographic ventricular images. The technique produces results including a degree of radial ventricular asynchrony in heart failure patients with ventricular conduction delay to predict a magnitude of contractile function improvement with pacing therapy. Quantification of change in ventricular regional wall motion asynchrony in response to a therapy provides for a means to identify candidates to receive the therapy and quantitatively predict the benefit of the therapy. Quantification of changes in ventricular regional wall motion asynchrony in response to a sequence of therapies provides for a means to determine an approximately optimal therapy for an intended patient response.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: October 22, 2013
    Assignee: Cardiac Pacemakers, Inc.
    Inventors: Andrew P. Kramer, Etienne Huvelle
  • Publication number: 20110190631
    Abstract: A phase analysis technique provides for quantification of regional wall motion asynchrony from endocardial border contours generated from two-dimensional echocardiographic ventricular images. The technique produces results including a degree of radial ventricular asynchrony in heart failure patients with ventricular conduction delay to predict a magnitude of contractile function improvement with pacing therapy. Quantification of change in ventricular regional wall motion asynchrony in response to a therapy provides for a means to identify candidates to receive the therapy and quantitatively predict the benefit of the therapy. Quantification of changes in ventricular regional wall motion asynchrony in response to a sequence of therapies provides for a means to determine an approximately optimal therapy for an intended patient response.
    Type: Application
    Filed: April 12, 2011
    Publication date: August 4, 2011
    Inventors: Andrew P. Kramer, Etienne Huvelle
  • Patent number: 7974694
    Abstract: A phase analysis technique provides for quantification of regional wall motion asynchrony from endocardial border contours generated from two-dimensional echocardiographic ventricular images. The technique produces results including a degree of radial ventricular asynchrony in heart failure patients with ventricular conduction delay to predict a magnitude of contractile function improvement with pacing therapy. Quantification of change in ventricular regional wall motion asynchrony in response to a therapy provides for a means to identify candidates to receive the therapy and quantitatively predict the benefit of the therapy. Quantification of changes in ventricular regional wall motion asynchrony in response to a sequence of therapies provides for a means to determine an approximately optimal therapy for an intended patient response.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: July 5, 2011
    Assignee: Cardiac Pacemakers, Inc.
    Inventors: Andrew P. Kramer, Etienne Huvelle
  • Patent number: 7062326
    Abstract: An intracardiac impedance-derived parameter, Half Cycle Activity (HCA) is used in sensing and controlling cardiac activities in implantable cardiac devices such as bradycardia pacemakers and cardioverter defibrillators. This impedance-derived parameter correlates closely with physical workload and at the same time provides hemodynamic feedback information. Thus, it allows a pacemaker system to implement accurately an increase in hemodynamically driven pacing rate, as well as to limit an inappropriate decrease of driven pacing rate advised by another sensor such as an accelerometer. In addition, it determines the maximum pacing rate for the pacemaker so as to prevent hemodynamic compromise. Therefore, the HCA parameter may be used to determine a Hemodynamic Upper Rate Limit and a Hemodynamic Lower Rate Limit, and thus define a Hemodynamic Pacing Range that is compatible with the range of physiological rate. This allows a closed-loop control of the pacing rate.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: June 13, 2006
    Assignee: Cardiac Pacemakers, Inc.
    Inventors: Etienne Huvelle, Francisca Cuesta Sanchez
  • Publication number: 20060116731
    Abstract: A phase analysis technique provides for quantification of regional wall motion asynchrony from endocardial border contours generated from two-dimensional echocardiographic ventricular images. The technique produces results including a degree of radial ventricular asynchrony in heart failure patients with ventricular conduction delay to predict a magnitude of contractile function improvement with pacing therapy. Quantification of change in ventricular regional wall motion asynchrony in response to a therapy provides for a means to identify candidates to receive the therapy and quantitatively predict the benefit of the therapy. Quantification of changes in ventricular regional wall motion asynchrony in response to a sequence of therapies provides for a means to determine an approximately optimal therapy for an intended patient response.
    Type: Application
    Filed: February 8, 2006
    Publication date: June 1, 2006
    Inventors: Andrew Kramer, Etienne Huvelle
  • Patent number: 7041061
    Abstract: A phase analysis technique provides for quantification of regional wall motion asynchrony from endocardial border contours generated from two-dimensional echocardiographic ventricular images. The technique produces results including a degree of radial ventricular asynchrony in heart failure patients with ventricular conduction delay to predict a magnitude of contractile function improvement with pacing therapy. Quantification of change in ventricular regional wall motion asynchrony in response to a therapy provides for a means to identify candidates to receive the therapy and quantitatively predict the benefit of the therapy. Quantification of changes in ventricular regional wall motion asynchrony in response to a sequence of therapies provides for a means to determine an approximately optimal therapy for an intended patient response.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: May 9, 2006
    Assignee: Cardiac Pacemakers, Inc.
    Inventors: Andrew P. Kramer, Etienne Huvelle
  • Publication number: 20040015081
    Abstract: A phase analysis technique provides for quantification of regional wall motion asynchrony from endocardial border contours generated from two-dimensional echocardiographic ventricular images. The technique produces results including a degree of radial ventricular asynchrony in heart failure patients with ventricular conduction delay to predict a magnitude of contractile function improvement with pacing therapy. Quantification of change in ventricular regional wall motion asynchrony in response to a therapy provides for a means to identify candidates to receive the therapy and quantitatively predict the benefit of the therapy. Quantification of changes in ventricular regional wall motion asynchrony in response to a sequence of therapies provides for a means to determine an approximately optimal therapy for an intended patient response.
    Type: Application
    Filed: March 28, 2003
    Publication date: January 22, 2004
    Inventors: Andrew P. Kramer, Etienne Huvelle
  • Publication number: 20030114889
    Abstract: An intracardiac impedance-derived parameter, Half Cycle Activity (HCA) is used in sensing and controlling cardiac activities in implantable cardiac devices such as bradycardia pacemakers and cardioverter defibrillators. This impedance-derived parameter correlates closely with physical workload and at the same time provides hemodynamic feedback information. Thus, it allows a pacemaker system to implement accurately an increase in hemodynamically driven pacing rate, as well as to limit an inappropriate decrease of driven pacing rate advised by another sensor such as an accelerometer. In addition, it determines the maximum pacing rate for the pacemaker so as to prevent hemodynamic compromise. Therefore, the HCA parameter may be used to determine a Hemodynamic Upper Rate Limit and a Hemodynamic Lower Rate Limit, and thus define a Hemodynamic Pacing Range that is compatible with the range of physiological rate. This allows a closed-loop control of the pacing rate.
    Type: Application
    Filed: February 6, 2003
    Publication date: June 19, 2003
    Applicant: Cardiac Pacemakers, Inc.
    Inventors: Etienne Huvelle, Francisca Cuesta Sanchez
  • Patent number: 6522914
    Abstract: An intracardiac impedance-derived parameter, Half Cycle Activity (HCA) is used in sensing and controlling cardiac activities in implantable cardiac devices such as bradycardia pacemakers and cardioverter defibrillators. This impedance-derived parameter correlates closely with physical workload and at the same time provides hemodynamic feedback information. Thus, it allows a pacemaker system to implement accurately an increase in hemodynamically driven pacing rate, as well as to limit an inappropriate decrease of driven pacing rate advised by another sensor such as an accelerometer. In addition, it determines the maximum pacing rate for the pacemaker so as to prevent hemodynamic compromise. Therefore, the HCA parameter may be used to determine a Hemodynamic Upper Rate Limit and a Hemodynamic Lower Rate Limit, and thus define a Hemodynamic Pacing Range that is compatible with the range of physiological rate. This allows a closed-loop control of the pacing rate.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: February 18, 2003
    Assignee: Cardiac Pacemakers, Inc.
    Inventors: Etienne Huvelle, Francisca Cuesta Sanchez